The Effectiveness of Conversational AI Service (chatbot) Utilization on Vaccine Confidence

Last updated: December 3, 2024
Sponsor: The University of Hong Kong
Overall Status: Completed

Phase

N/A

Condition

N/A

Treatment

Conversational AI Service (Chatbot)

Clinical Study ID

NCT05424952
UW 21-659
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The primary objective of this study is to develop and evaluate a conversational AI service (chatbot) on social media platforms to obtain accurate and up-to-date vaccine information, and assess the impact of chatbot usage on users' vaccine confidence and acceptance in Hong Kong, Singapore, and Thailand.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Hong Kong adult residents (English or Chinese users) with (a) unvaccinated seniorparents/grandparents aged 60 (including those who received first dose after theannouncement of the COVID passport on 4th of January) or (b) unvaccinated childrenaged below 18.

  • Thailand adult residents (Thai users) with (a) unvaccinated seniorparents/grandparents aged 60 or above or (b) unvaccinated children aged below 18.

  • Singapore adult residents (English or Chinese users) with unvaccinated children agedbetween 5 to 11 years old.

Exclusion

Exclusion Criteria:

  • People who do not meet the inclusion criteria.

Study Design

Total Participants: 1000
Treatment Group(s): 1
Primary Treatment: Conversational AI Service (Chatbot)
Phase:
Study Start date:
February 11, 2022
Estimated Completion Date:
February 17, 2023

Study Description

The investigators will focus on vulnerable seniors and/or children from Hong Kong, Singapore and Thailand who have refused or delayed COVID-19 vaccination. Participants will be recruited by an online panel to meet the target quota by age and sex. Participants will then be randomly assigned to the intervention group and the control group. For both intervention and control groups, evaluation questionnaires will be given out to the study participants asking questions about their demographics, including age, sex, educational level, employment status and household income levels. Participants will then answer questions regarding COVID-19 vaccine confidence, including the effectiveness and safety of vaccines, and the motivations of the policymakers who decided on the needed vaccines. Participants will be asked about COVID-19 vaccine acceptance including the intention to receive COVID-19 vaccines, make plans to receive COVID-19 vaccines, and receive at least one dose of COVID-19 vaccines. The intervention group will then be asked to use the chatbot developed by the research team for up to two weeks. The chatbot is developed under the RE-AIM framework for formative, impact, and process evaluation of the intervention. The control group will have no exposure to the chatbot.

The chatbot will be supported with data from 1) social listening analytics for monitoring local real-time discourses in the digital space on COVID-19 vaccine hesitancy and misinformation, and 2) formative, baseline, and endpoint evaluation, which will generate evidence for development and improvement/refinement.

Connect with a study center

  • The University of Hong Kong

    Hong Kong,
    Hong Kong

    Site Not Available

  • National University of Singapore

    Singapore,
    Singapore

    Site Not Available

  • Health Intervention and Technology Assessment Program

    Bangkok,
    Thailand

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.